Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.40 | 15.50 | -0.18% |
CAC 40 | 7,712.63 | 16.36 | 0.21% |
DAX 40 | 23,960.52 | 173.07 | 0.73% |
Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
FTSE 100 | 8,836.19 | 13.28 | 0.15% |
HKSE | 23,887.83 | 28.23 | -0.12% |
NASDAQ | 20,601.10 | 207.97 | 1.02% |
Nikkei 225 | 39,587.68 | 223.20 | -0.56% |
NZX 50 Index | 12,764.95 | 1.65 | -0.01% |
S&P 500 | 6,279.35 | 51.93 | 0.83% |
S&P/ASX 200 | 8,589.30 | 13.70 | -0.16% |
SSE Composite Index | 3,473.13 | 0.81 | 0.02% |